RCC | Docwire News

RCC

Charlotte RobinsonNephrology Times | July 25, 2024

In a phase 2 study, adding tivozanib to nivolumab did not show a benefit for renal cell carcinoma treatment.

Charlotte RobinsonNephrology Times | July 16, 2024

The FDA granted Fast Track designation to ADI-270 for treating metastatic or advanced clear cell renal cell carcinoma.

Pavlos Msaouel, MD, PhDOncology | February 12, 2024

What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib?

Victoria SochaASCO 2019 | August 29, 2019

Treatment for advanced renal cell carcinoma (aRCC) commonly includes immune-oncology therapies and tyrosine kinase ...

Kerri FitzgeraldOncology | April 24, 2019

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda®) in combination with axitinib (Inlyta®) for ...